热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
Brilliant Violet 510™ anti-mouse CD45 Antibo
产品名称：
Brilliant Violet 510™ anti-mouse CD45 Antibo
产品类别：
抗体
产品编号：
103137
产品应用：
103137
[价格]
规格 价格 库存
125µL ￥ 2184 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510? under optimal conditions.
Concentration
?g sizes: 0.2 mg/mL
?L sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the ?g size, the suggested use of this reagent is ≤0.5 ?g per million cells in 100 ?l volume. For immunofluorescent staining using the ?l size, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 510? excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5,?immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Application References

(PubMed link indicates BioLegend citation)
  1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
  2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
  3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
  4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
  5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
  6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
  7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
  8. Liu F, et al. 2012. Blood. 119:3295. PubMed
  9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
  10. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  11. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  2. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  3. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  4. Leslie J, et al. 2021. Sci Rep. 11:1415. PubMed
  5. Mackel JJ, et al. 2022. Front Cell Infect Microbiol. 12:974175. PubMed
  6. Cornax I, et al. 2021. Microorganisms. 9:00. PubMed
  7. Benitez AA, et al. 2020. Commun Biol. 0.371527778. PubMed
  8. Gawish R, et al. 2022. Elife. 11:. PubMed
  9. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  10. Boal-Carvalho I, et al. 2020. EMBO Rep. 21:e50421. PubMed
  11. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  12. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  13. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  14. Dong L, et al. 2021. Cancer Cell. . PubMed
  15. Pan XX, et al. 2021. Front Cell Dev Biol. 637424:9. PubMed
  16. Scott CL et al. 2018. Immunity. 49(2):312-325 . PubMed
  17. Lancaster JN, et al. 2019. Nat Commun. 10:2220. PubMed
  18. Zhang K, et al. 2018. PLoS Pathog. 14:e1006925. PubMed
  19. Li Y, et al. 2021. Basic Res Cardiol. 116:30. PubMed
  20. Poli V, et al. 2021. iScience. 24:103256. PubMed
  21. Matsumoto R, et al. 2021. Front Pharmacol. 12:715752. PubMed
  22. Alam J, et al. 2022. Mucosal Immunol. 15:620. PubMed
  23. Devalaraja S, et al. 2020. Cell. 1098:180. PubMed
  24. Upadhyaya P, et al. 2021. J Immunother Cancer. 9:00. PubMed
  25. Hiraishi Y, et al. 2018. Sci Rep. 8:18052. PubMed
  26. Wang L, et al. 2022. Cancer Res Commun. 2:518. PubMed
  27. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  28. Wang Y, et al. 2021. Cancer Cell. :. PubMed
  29. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  30. Di Gioia M, et al. 2020. Nat Immunol. 21:42. PubMed
  31. Somerville TD, et al. 2020. eLife. 9:e53381.. PubMed
  32. Lees JG, et al. 2020. PLoS One. 15:e0238164. PubMed
  33. Sun Q, et al. 2022. Cell Death Dis. 13:724. PubMed
  34. Yoshihara E, et al. 2020. Nature. 606:586. PubMed
  35. Huang X, et al. 2020. Cell Host Microbe. 29(2):210-221.e6. PubMed
  36. LaMarche NM, et al. 2020. Cell Metabolism. 32(2):243-258.e6. PubMed
  37. Cuff AO, et al. 2020. Frontiers in Immunology. 1.930555556. PubMed
  38. Thanabalasuriar A et al. 2019. Cell Host Microbe. 25(4):526-536 . PubMed
  39. Yu M, et al. 2021. J Clin Invest. 131:. PubMed
  40. Ma M, et al. 2021. Front Immunol. 12:718779. PubMed
  41. Xu Y, et al. 2021. Stem Cell Res Ther. 12:112. PubMed
  42. Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed
  43. Devalaraja S, et al. 2020. STAR Protoc. 1:100188. PubMed
  44. Pandey V, et al. 2021. eLife. 0.416666666666667. PubMed
  45. Taguchi K, et al. 2015. J Urol. . PubMed
  46. Duc D et al. 2019. Cell Rep. 29(2):378-390 . PubMed
  47. Linde N, et al. 2018. Nat Commun. 9:21. PubMed
  48. Wang H, et al. 2021. Malar J. 20:249. PubMed
  49. Taguchi K, et al. 2014. J Am Soc Nephrol. 25:1680. PubMed
  50. Tyagi AM, et al. 2021. eLife. 10:00. PubMed
  51. Neupane AS, et al. 2020. Cell. 183(1):110-125.e11. PubMed
  52. Thiriot A et al. 2017. BMC biology. 15(1):45 . PubMed
  53. Knolle MD et al. 2018. Frontiers in immunology. 1.925 . PubMed
  54. Linehan JL et al. 2018. Cell. 172(4):784-796 . PubMed
  55. Kooreman NG et al. 2018. Cell stem cell. 22(4):501-513 . PubMed
  56. Bonnardel J, et al. 2019. Immunity. 51:638. PubMed
  57. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  58. Yang P, et al. 2022. Nat Commun. 13:5782. PubMed
  59. Weaver JD, et al. 2022. Oncoimmunology. 11:2141007. PubMed
  60. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  61. Dang MT, et al. 2021. Cell Reports. 34(13):108917. PubMed
  62. Nagai M, et al. 2020. Cell. 178(5):1072-1087.e14.. PubMed
  63. Silver J, et al. 2020. Methods Mol Biol. 2121:115. PubMed
  64. Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed
  65. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  66. Panea C, et al. 2021. Commun Biol. 4:913. PubMed
  67. Lima-Junior DS, et al. 2021. Cell. . PubMed
  68. Jacobson A et al. 2018. Cell host & microbe. 24(2):296-307 . PubMed
  69. Casulli J, et al. 2019. Nat Commun. 10:2121. PubMed
  70. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
  71. Alam J, et al. 2021. Front Immunol. 12:701415. PubMed
  72. Jorapur A, et al. 2022. PLoS Pathog. 18:e1010200. PubMed
  73. Kalavska K, et al. 2021. Int J Mol Sci. 22:. PubMed
  74. Frenis K, et al. 2021. Basic Res Cardiol. 31:116. PubMed
  75. Dewi IMW, et al. 2021. Cell Reports Medicine. 2(5):100289. PubMed
  76. Walsh SM, et al. 2021. eLife. 10:00. PubMed
  77. LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed
  78. Guilliams M, et al. 2022. Cell. 185:379. PubMed
  79. Stacy A, et al. 2021. Cell. 184(3):615-627.e17. PubMed
  80. Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed
  81. Xiao Y, et al. 2018. Int Immunol. 30:457. PubMed
  82. Ayari A, et al. 2020. Commun Biol. 3:237. PubMed
  83. Dang MT, et al. 2021. STAR Protoc. 2:100957. PubMed
  84. Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed
  85. Louka E, et al. 2021. Journal of Experimental Medicine. 218(2):. PubMed
  86. Holm J, et al. 2015. PLoS One. 10:125495. PubMed
  87. Jordan S, et al. 2020. Cell. 178(5):1102-1114.e17.. PubMed
  88. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  89. Kalavska K, et al. 2022. Front Oncol. 12:858797. PubMed
  90. Zhang XW, et al. 2021. Oncoimmunology. 10:1920739. PubMed
  91. Zeis P, et al. 2020. Immunity. 53:775. PubMed
  92. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  93. Tian Y, et al. 2020. JCI Insight. 5:00. PubMed
  94. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  95. Hoffmann J, et al. 2021. Nat Commun. 12:3964. PubMed
  96. Carlson PM, et al. 2021. J Immunol. 207:720. PubMed
  97. Seki N, et al. 2022. iScience. 25:104838. PubMed
  98. Chen H, et al. 2022. Mol Ther Methods Clin Dev. 27:431. PubMed
  99. Montalban-Arques A, et al. 2021. Cell Host Microbe. :. PubMed
  100. Asadi Shahmirzadi A, et al. 2020. Cell Metabolism. 32(3):447-456.e6. PubMed
  101. Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed
  102. Silva DA, et al. 2019. Nature. 565:186. PubMed
  103. Xu JL, et al. 2022. Front Pharmacol. 13:911663. PubMed
  104. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  105. Halim TYF et al. 2018. Immunity. 48(6):1195-1207 . PubMed
  106. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  107. Sugita Y, et al. 2021. Oncol Rep. 45:. PubMed
  108. Zamarin D, et al. 2020. Clin Cancer Res. 26:4531. PubMed
  109. Domanska D, et al. 2022. J Exp Med. 219:. PubMed
  110. Liu J, et al. 2022. Nat Commun. 13:4308. PubMed
  111. Aulova KS, et al. 2022. Molecules. 27:. PubMed
  112. Xia L, et al. 2021. Cell Chemical Biology. 28(5):610-624.e5. PubMed
  113. Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. PubMed
  114. Ramanan D, et al. 2020. Cell. 181(6):1276-1290. PubMed
  115. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  116. Smith LK, et al. 2021. Elife. 10:. PubMed
  117. Catrysse L, et al. 2021. Cell Rep. 36:109748. PubMed
  118. Wang X, et al. 2021. Theranostics. 11:209. PubMed
  119. Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed
  120. Wang X, et al. 2021. Immunity. 54(6):1123-1136.e8. PubMed
  121. Wunderlich CM, et al. 2018. Nat Commun. 9:1646. PubMed
  122. Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed
  123. Tripathi A, et al. 2021. Mol Psychiatry. 26:3043. PubMed
  124. Jiang M, et al. 2021. Front Pharmacol. 12:657486. PubMed
  125. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  126. Sfakianos JP, et al. 2020. Nat Commun. 2.222222222. PubMed
  127. Deniset JF et al. 2019. Immunity. 51(1):131-140 . PubMed
  128. Weinstock A, et al. 2019. Immunometabolism. 1. PubMed
  129. Figueiredo CA, et al. 2022. J Neuroinflammation. 19:17. PubMed
  130. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID
AB_2561392 (BioLegend Cat. No. 103137) AB_2563061 (BioLegend Cat. No. 103138)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type
B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线